血清中EB病毒DNA作为儿童和青少年霍奇金淋巴瘤早期预后标志物
研究纳入儿童肿瘤协作组AHOD0031试验的儿童霍奇金淋巴瘤患者,在基线和治疗开始后8天检测无细胞血EBV DNA,基线EBV DNA与肿瘤EBV相关,治疗8天后EBV DNA预测无事件生存较差。
要点
- 基线无细胞血EBV DNA与肿瘤中EBV存在相关
- 治疗开始后8天EBV DNA可预测较差的 无事件生存
- 无细胞血EBV DNA作为霍奇金淋巴瘤肿瘤反应不足标志物需进一步研究
核心结论
- 无细胞血EBV DNA作为霍奇金淋巴瘤肿瘤反应不足标志物需进一步研究。
研究设计与样本
- 研究纳入儿童肿瘤协作组AHOD0031试验的儿童患者,在基线和治疗开始后8天检测无细胞血EBV DNA。
主要发现
- 基线时无细胞血EBV DNA与肿瘤中EBV存在相关。
- 治疗开始后8天EBV DNA预测较差的无事件生存。
局限性
- 原文结论指出无细胞血EBV DNA作为霍奇金淋巴瘤肿瘤反应不足标志物需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children's Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.
引用
- Welch JJG, Schwartz CL, Higman M, et al. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv. 2017. PMID: 29296710. doi:10.1182/bloodadvances.2016002618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。